Developments YD Bio enters MOU to merge with EG BioMed YD Bio (NASDAQ: YDES) has announced that it has entered into a Memorandum of Understanding (MOU) to merge with closely held EG BioMed—a biotechnology company specializing in DNA methylation–based cancer diagnostics and... January 7, 2026